In conclusion, our study revealed a regulatory role for HBV-DNA-Pol in PD-L1-mediated immune escape in HCC, suggesting that HBV DNA polymerase is a potential target for HCC therapy. This evidence concerns the gene CD274 and hepatocellular carcinoma.